Atrium Therapeutics, Inc.

NASDAQ: RNA · Healthcare · Biotechnology

PublicHQ San Diego, CA · San DiegoCIK 0002093101Reports USD

#1 of 1,417 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 51

v0.1 · 5/100 weight · pillars only

↑ workforce scale, market scale · ↓ listing tenure, filing timeliness

Methodology →

Revenue TTM

—

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

—

Employees

511

as of 2026-08-01

Market cap

$194.1M

as of 2026-08-01

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

No filed financials — private or non-XBRL filer.

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Atrium Therapeutics, Inc.’s financial profile?

Atrium Therapeutics, Inc. has no structured financials on file — private or non-XBRL filer.

Peers · Healthcare

Galectin Therapeutics Inc.——PepGen Inc.——Cardiol Therapeutics Inc.——Acumen Pharmaceuticals, Inc.——Organigram Global Inc.——Conexeu Sciences Inc.——

Neighbors

San Diego →

QUALCOMM Incorporated$44.3B79B+Realty Income Corporation$5.7B61C Sempra$12.4B64C DexCom, Inc.$4.7B87A ResMed Inc.$5.1B88A Illumina, Inc.$4.3B84B+

Key facts

CEOKathleen Gallagher

SectorHealthcare

IndustryBiotechnology

HeadquartersSan Diego, CA

ExchangeNASDAQ: RNA

Employees511

IPO date2026-02-27

Latest filings

8-K2026-08-13 10-Q2026-08-13 8-K2026-07-14 8-K2026-05-14 10-Q2026-05-14 8-K2026-02-27 8-K2026-02-26

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.